In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Perrigo gets rights to sell generic form of Nycomed's Cutivate lotion

Executive Summary

In its second settlement agreement this month for Cutivate (fluticasone), Nycomed US Inc. (a division of Nycomed International Management GMBH) has granted Perrigo Co. the right to launch a generic version of the drug for atopic dermatitis on September 22, 2012, or earlier pending certain circumstances. Nycomed, which gained FDA approval for Cutivate in early 2005, also licensed Glenmark Generics rights to market a generic version of the drug in March 2012. Cutivate has annual sales of about $50mm.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies